These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29909564)

  • 21. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval.
    Prange A; Bokhof B; Polzer P; Tio J; Radke I; Heidinger O; Heindel W; Weigel S
    Rofo; 2019 Feb; 191(2):130-136. PubMed ID: 30103233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Breast Cancer Res Treat; 2011 Apr; 126(3):671-8. PubMed ID: 20814817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms.
    Bae MS; Han W; Koo HR; Cho N; Chang JM; Yi A; Park IA; Noh DY; Choi WS; Moon WK
    Cancer Sci; 2011 Oct; 102(10):1862-7. PubMed ID: 21752153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States.
    Hernandez RK; Quach D; Wade SW; Pirolli M; Quigley J; Narod SA; Liede A
    Breast Cancer Res Treat; 2014 Aug; 146(3):637-46. PubMed ID: 25053278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
    Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
    Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
    Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
    Dong XF; Wang Y; Huang BF; Hu GN; Shao JK; Wang Q; Tang CH; Wang CQ
    Biomed Res Int; 2020; 2020():8823270. PubMed ID: 33134390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
    Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
    Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.